Saint Maur Des Fosses

This research aims to evaluate the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis. The study is conducted in France and focuses on understanding how this treatment performs outside of controlled clinical trial settings. Participants in this observational study will be newly starting deucravacitinib as prescribed by their treating clinician. There are no additional study treatments or placebo groups, as the study observes the outcomes of the treatment during routine clinical care. During the study, researchers will assess clinical outcomes including the Physician's Global Assessment (PGA) and the Dermatology Life Quality Index (DLQI) at baseline and at months 4, 12, 18 (optional), and 24. They will also monitor how long participants remain on deucravacitinib treatment, up to 24 months. These evaluations help to measure both the effectiveness and impact on quality of life for participants with plaque psoriasis.

Researchers are evaluating the safety and performance of hyaluronic acid-based dermal fillers designed to enhance facial features such as the lips, perioral lines, nasolabial folds, cheeks, and infraorbital hollows. This post-market study aims to confirm how long the effects of these fillers last when used in real-life conditions on adults aged 18 years and older seeking aesthetic treatment. The fillers use COLD-X1932 technology by Symatese to modify skin anatomy and facial appearance. Participants will receive facial injections of these dermal fillers and attend follow-up visits every 6 months for up to 24 months. During these visits, the investigator will assess the treated areas using specific 5- or 6-point scales to determine if the area has returned to its pre-injection state. If desired, participants may receive retreatment at the 12- or 18-month follow-up if their treated areas have returned to baseline. Throughout the study, participants will undergo simple clinical examinations to monitor safety and performance. They will also evaluate their own aesthetic improvement compared to before treatment and report the pain level experienced during the initial injection. The main outcome measured is the number of patients whose treated areas return to their baseline state at each follow-up visit conducted at 6, 12, 18, and 24 months.

Researchers are conducting a French prospective observational study to understand how patients aged 18 years and older with moderate to severe atopic dermatitis (AD) are managed when eligible for or currently receiving systemic therapy. The study aims to describe treatment patterns, including previous and current therapies, and monitor drug survival and compliance over time. Experienced dermatologists in hospital and office settings will participate, ensuring treatment decisions reflect real-world clinical practice. Patients will be followed for one year under routine care, with systemic treatment decisions made solely by their physicians independent of study enrollment. The study does not involve specific interventions or changes in treatment but observes the use and management of systemic therapies for AD, including topical corticosteroid use and other systemic options. Participants will complete questionnaires and undergo assessments at baseline, six months, and twelve months. Researchers will collect data on previous and current treatments, therapeutic management of atopic comorbidities, drug survival changes, and treatment adherence. The study focuses on gathering real-life information on systemic therapy use and patient outcomes over the 12-month follow-up period.

Researchers are investigating how the bacteria Bordetella pertussis and the immune response affect the severity of whooping cough in children. The study addresses important gaps in understanding how current vaccines influence bacterial gene expression and disease variation, especially in severe cases seen in infants. It aims to find gene and immune system patterns linked to disease severity and to identify potential biomarkers and new vaccine targets. The study involves collecting clinical data and biological samples, including deep nasal swabs and blood samples, from children diagnosed with pertussis. Researchers will analyze bacterial gene activity using a special panel of 200 genes related to virulence and vaccine antigens through transcriptomic methods. They will also study immune responses in these children to understand how the body reacts during infection. Participants will have nasal swabs and blood samples taken for testing. Scientists will measure bacterial gene expression, immune cell types, and plasma signaling proteins over a three-year period. The study includes detailed immune profiling and uses advanced laboratory techniques to monitor disease markers and immune responses, aiming to improve prediction of disease severity and guide future vaccine development.

Researchers are investigating urinary tract infections (UTIs), which are common bacterial infections frequently treated in general practice and represent the second most common community-acquired bacterial infection in France. UTIs account for 15% of antibiotic prescriptions in France, and many antibiotics used, except for cystitis treatments, are considered critical due to their role in promoting bacterial resistance. The study explores the idea that there are various clinical profiles of UTIs seen in general practice beyond the typical cystitis or pyelonephritis, including intermediate forms that may require different treatment approaches. This prospective multicenter cohort study aims to identify and characterize these different UTI profiles using clinical and bacteriological indicators. Participants are adult patients presenting with one or more clinical signs suggestive of a UTI during general practice consultations, with confirmation through urine dipstick tests or cytobacteriological urine examination. The study does not involve experimental treatments but observes real-life UTI cases to better understand the disease profiles and antibiotic use patterns. Participants will be monitored to determine the number and characteristics of homogeneous patient profiles with UTI by day 14 after completing antibiotic treatment. Researchers will collect clinical information and laboratory results to identify factors explaining longer antibiotic treatments in intermediate UTI forms. The study focuses on antibiotic resistance issues and aims to improve guidelines for UTI management in primary care. Participation duration depends on treatment and follow-up until day 14 after antibiotic therapy completion.

The emergence of extended-spectrum beta-lactamase-producing Enterobacteriaceae (E-ESBL) is an important public health concern, especially in children with urinary tract infections (UTIs). These bacteria can lead to increased use of penem antibiotics, which may cause resistant strains. This study evaluates the effects of different antibiotic treatments on the presence of E-ESBL in the digestive tract of children aged 3 months to under 3 years who have febrile UTIs. The goal is to compare the impact of intravenous amikacin versus intravenous or intramuscular ceftriaxone or oral cefixime on the emergence of these bacteria in stools. Participants receive one of the antibiotic treatments as monotherapy: amikacin given intravenously, ceftriaxone administered either intravenously or intramuscularly, or cefixime taken orally. Before starting treatment, an anorectal swab is collected to check for E-ESBL bacteria, and a second swab is taken three to four days after beginning the antibiotic therapy to monitor any changes. During the study, children are monitored for the presence of E-ESBL in their stools on day 4 through these swabs. Parents provide consent and confirm their understanding of the study information. The study measures the bacterial carriage in the digestive tract after treatment and ensures safety by excluding children currently hospitalized or on multiple antibiotics. The participation duration aligns with the timing of these assessments.